- Home
- VSTA vs PBYI Comparison
VSTA vs PBYI Comparison
Compare VSTA & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTA
- PBYI
- Stock Information
- Founded
- VSTA 1966
- PBYI 2010
- Country
- VSTA Brazil
- PBYI United States
- Employees
- VSTA N/A
- PBYI N/A
- Industry
- VSTA Other Consumer Services
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- VSTA Real Estate
- PBYI Health Care
- Exchange
- VSTA Nasdaq
- PBYI Nasdaq
- Market Cap
- VSTA 187.6M
- PBYI 153.2M
- IPO Year
- VSTA 2020
- PBYI N/A
- Fundamental
- Price
- VSTA $2.50
- PBYI $2.98
- Analyst Decision
- VSTA Sell
- PBYI Strong Buy
- Analyst Count
- VSTA 2
- PBYI 1
- Target Price
- VSTA $3.00
- PBYI $7.00
- AVG Volume (30 Days)
- VSTA 241.6K
- PBYI 808.8K
- Earning Date
- VSTA 11-07-2024
- PBYI 02-27-2025
- Dividend Yield
- VSTA N/A
- PBYI N/A
- EPS Growth
- VSTA N/A
- PBYI 492.79
- EPS
- VSTA N/A
- PBYI 0.47
- Revenue
- VSTA $280,865,717.00
- PBYI $243,569,000.00
- Revenue This Year
- VSTA $12.97
- PBYI N/A
- Revenue Next Year
- VSTA $11.26
- PBYI N/A
- P/E Ratio
- VSTA N/A
- PBYI $6.41
- Revenue Growth
- VSTA 6.41
- PBYI 6.30
- 52 Week Low
- VSTA $1.60
- PBYI $2.23
- 52 Week High
- VSTA $4.26
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- VSTA 59.02
- PBYI 46.28
- Support Level
- VSTA $2.12
- PBYI $2.92
- Resistance Level
- VSTA $2.44
- PBYI $4.06
- Average True Range (ATR)
- VSTA 0.16
- PBYI 0.25
- MACD
- VSTA 0.03
- PBYI -0.04
- Stochastic Oscillator
- VSTA 83.33
- PBYI 5.26
About VSTA Vasta Platform Limited
Vasta Platform Ltd operates as an education company in Brazil, engaged in providing end-to-end educational and digital solutions that cater to all needs of private schools operating in the K-12 educational segment. Its business segments are Content and EdTech Platform, and Digital Platform. The Content and EdTech platform derives its results from educational content solutions through digital and printed content, including textbooks, learning systems and other complementary educational services. The Digital Platform enables private schools to aggregate multiple learning strategies and helps them to focus on education through the Business' physical and digital e-commerce platform and other digital services.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.